FDA is advised to reject wider use of Amgen's Xgeva

02/8/2012 | Reuters

An expert panel urged the FDA not to approve Amgen's Xgeva for delaying the spread of prostate cancer to the bone, saying the drug's benefits do not outweigh the risk of developing osteonecrosis of the jaw. Xgeva provides a meaningful benefit, and is being tested against other cancers, including breast, lung and multiple myeloma, Amgen said. The FDA will issue a final ruling by April 26.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD